

Table S3. Post-vaccination immunogenicity for participants aged 6–23 months

Measure	Strain	Half dose of IIV4		Full dose of IIV4		Comparison (95% CI)
		N	Value (95% CI)	N	Value (95% CI)	
HAI GMT	A(H1N1)	274	119 (95.5–148)	293	212 (173–259)	1.78 (1.32–2.39) ^a
	A(H3N2)	277	130 (109–156)	296	201 (170–237)	1.54 (1.21–1.97) ^a
	B/Victoria	274	157 (128–191)	293	217 (179–263)	1.38 (1.05–1.83) ^a
	B/Yamagata	277	146 (122–175)	296	229 (193–273)	1.57 (1.22–2.01) ^a
Seroconversion rate (%)	A(H1N1)	245	73.9 (67.9–79.3)	252	81.3 (76.0–86.0)	7.5 (0.139–14.7) ^b
	A(H3N2)	248	81.0 (75.6–85.7)	255	89.4 (85.0–92.9)	8.4 (2.16–14.6) ^b
	B/Victoria	245	82.4 (77.1–87.0)	252	82.5 (77.3–87.0)	0.1 (–6.60–6.81) ^b
	B/Yamagata	248	83.5 (78.2–87.9)	254	87.0 (82.2–90.9)	3.5 (–2.69–9.80) ^b
Post- to pre- vaccination GMT ratio	A(H1N1)	245	7.44 (6.22–8.91)	252	13.1 (10.7–16.0)	-
	A(H3N2)	248	11.9 (9.91–14.4)	255	18.4 (15.3–22.0)	-

Measure	Strain	Half dose of IIV4		Full dose of IIV4		Comparison (95% CI)
		N	Value (95% CI)	N	Value (95% CI)	
	B/Victoria	245	11.6 (9.66–13.8)	252	15.2 (12.5–18.4)	-
	B/Yamagata	248	11.4 (9.62–13.5)	254	16.6 (13.8–19.9)	-

Immunogenicity was assessed according to the vaccine received in all participants in the immunogenicity subset who received at least one dose of the study vaccine, had a valid post-vaccination serology result for at least one strain, and completed the study according to protocol. Abbreviations: CI, confidence interval; GMT, geometric mean titer; HAI, hemagglutination inhibition; IIV4, quadrivalent split-virion inactivated influenza vaccine; -, not calculated/determined.

^a Ratio of HAI GMTs (full dose/half dose).

^b Difference in seroconversion rate: seroconversion rate for the full dose of IIV4 minus the seroconversion rate for the half dose of IIV4.